Health News from Medical News Today: Plexxikon Announces Combination Trials For Vemurafenib In Melanoma

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Plexxikon Announces Combination Trials For Vemurafenib In Melanoma 3 Jun 2011, 5:00 pm Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced new clinical trials in metastatic melanoma testing vemurafenib (PLX4032/RG7204) in combination with other state-of-the-art treatments, including an immunologic therapy and an investigational MEK inhibitor. Additionally, a new trial will test vemurafenib as a single agent in thyroid cancer patients who have the BRAF mutation. Vemurafenib targets the mutant BRAF protein, which is present in about half of melanomas, about 40-70 percent of thyroid cancer and about eight percent of all solid tumors... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.